VYNE Phase 2b Repibresib vitiligo trial misses F-VASI50, terminates extension, seeks partner

VYNE Therapeutics Inc.

Primary endpoint F-VASI50 at Week 24 not met: 19.5% for 3% vs 23.4% vehicle (p=0.1245).
Key secondary endpoint F-VASI75 also not met (9.8% vs 6.4%, p=0.1468).
Nominal statistical significance for 3% dose on percent CFB in F-VASI (-43.6% vs -25.6%, p=0.002) and T-VASI (-28.3% vs -16.2%, p=0.044).
High vehicle effect and dropout rate in active arms (36.6% for 3% vs 10.6% vehicle); company ends trial extension phase.
Preliminary cash $39.6M as of June 30, 2025; company seeking partner for Repibresib.

item 2.02item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.